Tag: Ki67

Articles

• Ki-67-based breast cancer recurrence data
• Tumor proliferation, as measured by Ki-67, predicts BC outcomes

News

09/17/17

KI-67 linked to survival in women with luminal breast cancer

04/28/12

Ki67 proliferation index predicts progression of LCIS

Studies

• Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features Cite
  Sandilya U, K M. Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features. Cureus. Springer Science and Business Media LLC; 2024; 10.7759/cureus.69820
• The association between dietary acid load index with tumor stage and size, histological grade, Ki-67 marker, and the odds of breast cancer: A case-control study based on hospital evidence Cite
  Khodabakhshi A, Nasab SAR, Rafeeinia A, Hesami S, Bazyar H, Aghamohammadi V. The association between dietary acid load index with tumor stage and size, histological grade, Ki-67 marker, and the odds of breast cancer: A case-control study based on hospital evidence. Springer Science and Business Media LLC; 2024; 10.21203/rs.3.rs-4873761/v1
• Efficacy of pre-surgical short-term endocrine therapy during the waiting period for surgery in post-menopausal hormone receptor-positive breast cancer Cite
  Maeda Y, Sato A, Matsumoto A, Ikeda T, Jinno H. Efficacy of pre-surgical short-term endocrine therapy during the waiting period for surgery in post-menopausal hormone receptor-positive breast cancer. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4490367/v1
• The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer Cite
  Rewcastle E, Skaland I, Gudlaugsson E, Fykse SK, Baak JPA, Janssen EAM. The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07352-4
• Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC. Cite
  Urruticoechea A, Martinez P, Hernando C, Recalde S, Sanchez Munoz A, Morales D, et al. Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 42:556-556 10.1200/jco.2024.42.16_suppl.556
• Heart Failure Post-Myocardial Infarction Promotes Mammary Tumor Growth Through the NGF-TRKA Pathway Cite
  Tani T, Oikawa M, Misaka T, Ishida T, Takeishi Y. Heart Failure Post-Myocardial Infarction Promotes Mammary Tumor Growth Through the NGF-TRKA Pathway. JACC: CardioOncology. Elsevier BV; 2024; 6:55-66 10.1016/j.jaccao.2023.10.002
• Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study Cite
  Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, et al. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. European Journal of Cancer. Elsevier BV; 2023; 195:113397 10.1016/j.ejca.2023.113397
• Implementation of Digital Image Analysis in Assessment of Ki67 Index in Breast Cancer Cite
  Vanderschelden RK, Jerome JA, Gonzalez D, Seigh L, Carter GJ, Clark BZ, et al. Implementation of Digital Image Analysis in Assessment of Ki67 Index in Breast Cancer. Applied Immunohistochemistry & Molecular Morphology. Ovid Technologies (Wolters Kluwer Health); 2023; 10.1097/pai.0000000000001171
• AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer Cite
  Lu W, Lashen AG, Wahab N, Miligy IM, Jahanifar M, Toss M, et al. AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer. The Journal of Pathology: Clinical Research. Wiley; 2023; 10.1002/cjp2.346
• Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis Cite
  Martins-Branco D, Nader-Marta G, Molinelli C, Ameye L, Paesmans M, Ignatiadis M, et al. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis. European Journal of Cancer. Elsevier BV; 2023;:113358 10.1016/j.ejca.2023.113358
• Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience Cite
  Li W, Lu N, Chen C, Lu X. Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience. Journal of International Medical Research. SAGE Publications; 2023; 51 10.1177/03000605231195468
• Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial Cite
  Nielsen TO, Leung SCY, Riaz N, Mulligan AM, Kos Z, Bane A, et al. Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial. Histopathology. Wiley; 2023; 10.1111/his.15032
• 62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis? Cite
  Bellet-Ezquerra M, Pardo PG, Fasani R, Villacampa G, Portu M, Serna G, et al. 62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?. ESMO Open. Elsevier BV; 2023; 8:101286 10.1016/j.esmoop.2023.101286
• Young age is associated with inferior outcomes in early-stage luminal B breast cancer patients who undergo mastectomy Cite
  Hou J, Li L, Wang J, Huang X, Xue J, Wu J. Young age is associated with inferior outcomes in early-stage luminal B breast cancer patients who undergo mastectomy. Future Oncology. Future Medicine Ltd; 2023; 19:715-726 10.2217/fon-2023-0083
• Ki 67 Cut-off Level & mPEPI Score: Any Predictive Role for Neoadjuvant ‘Chemotherapy’ Efficacy in Locally Advanced HER2 Negative Luminal-like Breast Cancer? Cite
  Dogan M, Karacin C, Kaman O, Bulut ZM, Kiziltan G, Oksuzoglu B, et al. Ki 67 Cut-off Level & mPEPI Score: Any Predictive Role for Neoadjuvant ‘Chemotherapy’ Efficacy in Locally Advanced HER2 Negative Luminal-like Breast Cancer?. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2756296/v1
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) Cite
  Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01626-3
• Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy Cite
  Ma Y, Zhu M, Lv M, Yuan P, Chen X, Liu Z. Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy. Cancer Medicine. Wiley; 2023; 10.1002/cam4.5839
• Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients Cite
  Tong Y, Dai J, Huang J, Fei X, Shen K, Liu Q, et al. Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients. Scientific Reports. Springer Science and Business Media LLC; 2023; 13 10.1038/s41598-022-25206-1
• The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations Cite
  Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Cancers. MDPI AG; 2023; 15:808 10.3390/cancers15030808
• The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up Cite
  Lashen AG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up. Cancer. Wiley; 2023; 10.1002/cncr.34655
• Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer Cite
  Bergman R, Berko YA, Sanchez V, Sanders ME, Gonzalez-Ericsson PI, Arteaga CL, et al. Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06794-y
• Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice Cite
  Hacking SM, Wang Y. Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. Journal of Clinical and Translational Pathology. Xia & He Publishing; 2022; 000:000-000 10.14218/jctp.2022.00012
• Concordance between Ki‑67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint Cite
  Amezcua‑Gálvez J, Lopez‑Garcia C, Villarreal‑Garza C, Lopez‑Rivera V, Canavati‑Marcos M, Santuario‑Facio S, et al. Concordance between Ki‑67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. Molecular and Clinical Oncology. Spandidos Publications; 2022; 17 10.3892/mco.2022.2565
• A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer Cite
  Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncology. Future Medicine Ltd; 2022; 10.2217/fon-2022-0310
• Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease? Cite
  Kamata A, Hino K, Kamiyama K, Takasaka Y. Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?. Cureus. Cureus, Inc.; 2022; 10.7759/cureus.22804
• Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cite
  Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers. MDPI AG; 2022; 14:1898 10.3390/cancers14081898
• Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated with Trimodality Therapy Cite
  Song Z, Li C, Zhou D, Liu J, Qian X, Zhang J. Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated with Trimodality Therapy. Clinical Breast Cancer. Elsevier BV; 2022; 10.1016/j.clbc.2022.02.001
• Predictive and prognostic significance of BRCAness in HER2-negative breast cancer Cite
  Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, et al. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2022; 10.1007/s12282-021-01319-9
• EPV008/#139 Role of KI67 in predicting survival in RH+/HER2- breast cancer according to axillary nodal involvement Cite
  Mejri N, Berrazega Y, Rachdi H, Harhira I, Boussen H. EPV008/#139 Role of KI67 in predicting survival in RH+/HER2- breast cancer according to axillary nodal involvement. E-Posters. BMJ Publishing Group Ltd; 2021; 10.1136/ijgc-2021-igcs.75
• Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors Cite
  de Gregorio A, Friedl TWP, Hering E, Widschwendter P, de Gregorio N, Bekes I, et al. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. Oncology. S. Karger AG; 2021;:1-10 10.1159/000517490
• Prognostic Factors Affecting Disease-Free Survival in Triple-Negative Breast Cancer and Impact of Ki-67 Cite
  Koca B, Yildirim M, Kuru B. Prognostic Factors Affecting Disease-Free Survival in Triple-Negative Breast Cancer and Impact of Ki-67. Indian Journal of Surgery. Springer Science and Business Media LLC; 2021; 10.1007/s12262-021-03066-9
• Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score Cite
  Paik S, Kwon Y, Lee MH, Kim JY, Lee DK, Cho WJ, et al. Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00221-z
• Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancer Cite
  Lathrop K, Kaklamani V, Brenner A, Li R, Nazarullah A, Hackman S, et al. Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps5-31
• Invasive lobular carcinoma of the breast: the increasing importance of this special subtype Cite
  McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-020-01384-6
• Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Cite
  Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2020; 21:1443-1454 10.1016/s1470-2045(20)30458-7
• Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer Cite
  NISMAN B, ALLWEIS TM, CARMON E, KADOURI L, MALY B, MAIMON O, et al. Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2020; 40:6417-6428 10.21873/anticanres.14663
• Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold Cite
  Maltoni R, Palleschi M, Ravaioli S, Tumedei MM, Altini M, Bravaccini S. Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold. Diagnostic Pathology. Springer Science and Business Media LLC; 2020; 15 10.1186/s13000-020-01024-9
• Breast cancer in women younger than 35 years old Cite
  Zouzoulas D, Tsolakidis D, Gitas G, Zafrakas M, Goulis DG, Douganiotis G, et al. Breast cancer in women younger than 35 years old. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 302:721-730 10.1007/s00404-020-05695-z
• Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score Cite
  Robertson S, Acs B, Lippert M, Hartman J. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:161-175 10.1007/s10549-020-05752-w
• A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth Cite
  Collard M, Gallagher PE, Tallant EA. A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth. Integrative Cancer Therapies. SAGE Publications; 2020; 19:153473542091744 10.1177/1534735420917444
• Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam Cite
  Dang Cong T, Nguyen Thanh T, Nguyen Phan QA, Hoang Thi AP, Nguyen Tran BS, Nguyen Vu QH. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam. Asian Pacific Journal of Cancer Prevention. EpiSmart Science Vector Ltd; 2020; 21:1135-1142 10.31557/apjcp.2020.21.4.1135
• Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer Cite
  Ding Y, Ding K, Qian H, Yu X, Zou D, Yang H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0231895 10.1371/journal.pone.0231895
• Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study Cite
  Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 122:1747-1753 10.1038/s41416-020-0815-9
• The prognostic and predictive potential of Ki-67 in triple-negative breast cancer Cite
  Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-019-57094-3
• Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer Cite
  Kang Y, Lee H, Kim YG, Han J, Kim Y, Yoo T, et al. Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. Journal of Oncology. Hindawi Limited; 2019; 2019:1-8 10.1155/2019/7386734
• Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence Cite
  Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1234-9
• Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy Cite
  Rossi L, Verrico M, Tomao S, Ricci F, Fontana A, Spinelli GP, et al. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology. Springer Science and Business Media LLC; 2019; 85:105-111 10.1007/s00280-019-03981-5
• ER−/PR+/HER2− breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases Cite
  Arena V, Pennacchia I, Vecchio FM, Carbone A. ER−/PR+/HER2− breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases. The Breast Journal. Wiley; 2019; 25:381-385 10.1111/tbj.13236
• Muscadine Grape Extract Reduces Lung and Liver Metastasis in Mice with Triple Negative Breast Cancer in Association with Changes in the Gut Microbiome (P05-017-19) Cite
  Collard M, Austin N, Tallant A, Gallagher P. Muscadine Grape Extract Reduces Lung and Liver Metastasis in Mice with Triple Negative Breast Cancer in Association with Changes in the Gut Microbiome (P05-017-19). Current Developments in Nutrition. Oxford University Press (OUP); 2019; 3 10.1093/cdn/nzz030.p05-017-19
• Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients Cite
  Flores-Díaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus JA, et al. Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:243-249 10.1007/s10549-019-05234-8
• Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer Cite
  Fasching PA, Gass P, Häberle L, Volz B, Hein A, Hack CC, et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:617-625 10.1007/s10549-019-05198-9
• Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy Cite
  Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, et al. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. Journal of Translational Medicine. Springer Science and Business Media LLC; 2018; 16 10.1186/s12967-018-1679-0
• Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Cite
  Resende U, Cabello C, Oliveira Botelho Ramalho S, Zeferino L. Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Oncology. S. Karger AG; 2018; 95:229-238 10.1159/000489785
• Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery Cite
  Nakashima K, Uematsu T, Takahashi K, Nishimura S, Tadokoro Y, Hayashi T, et al. Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer. Springer Science and Business Media LLC; 2018; 26:206-214 10.1007/s12282-018-0914-0
• Risk factors for loco-regional recurrence after breast conserving surgery: impact of young age and surgical margin status in breast cancer patients Cite
  Vasigh M, Rahmani S, Omranipour R, Haghighat S, Olfatbakhsh E, Kenari AY. Risk factors for loco-regional recurrence after breast conserving surgery: impact of young age and surgical margin status in breast cancer patients. International Surgery Journal. Medip Academy; 2018; 5:2952 10.18203/2349-2902.isj20183713
• Abstract B30: Bovine leukemia virus in breast tissue linked to increased cell proliferation and breast cancer risk Cite
  Buehring GC, Shen H, Baltzell K, Sison J, Krishnamurty S, Lendez P, et al. Abstract B30: Bovine leukemia virus in breast tissue linked to increased cell proliferation and breast cancer risk. Metabolism. American Association for Cancer Research; 2018; 10.1158/1557-3125.advbc17-b30
• Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy Cite
  Cabrera‐Galeana P, Muñoz‐Montaño W, Lara‐Medina F, Alvarado‐Miranda A, Pérez‐Sánchez V, Villarreal‐Garza C, et al. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. The Oncologist. Wiley; 2018; 23:670-678 10.1634/theoncologist.2017-0396
• Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34. Cite
  Singer CF, Rudas M, Fesl C, Steger GG, Pfeiler G, Egle D, et al. Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:589-589 10.1200/jco.2018.36.15_suppl.589
• Assessment of Ki-67 as a potential biomarker in patients with breast cancer Cite
  Ragab HM, Samy N, Afify M, El Maksoud NA, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. Journal of Genetic Engineering and Biotechnology. Springer Science and Business Media LLC; 2018; 16:479-484 10.1016/j.jgeb.2018.03.002
• Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients Cite
  Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:35-43 10.1007/s10549-018-4730-1
• The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer Cite
  Thakur SS, Li H, Chan AMY, Tudor R, Bigras G, Morris D, et al. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer. PLOS ONE. Public Library of Science (PLoS); 2018; 13:e0188983 10.1371/journal.pone.0188983
• Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women Cite
  de Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-Neto J, Nahas EAP. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology. Elsevier BV; 2017; 174:284-289 10.1016/j.jsbmb.2017.10.009
• Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis Cite
  Gallardo A, Garcia-Valdecasas B, Murata P, Teran R, Lopez L, Barnadas A, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:31-37 10.1007/s10549-017-4486-z
• Breast cancer in young women and prognosis: How important are proliferation markers? Cite
  Fredholm H, Magnusson K, Lindström LS, Tobin NP, Lindman H, Bergh J, et al. Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer. Elsevier BV; 2017; 84:278-289 10.1016/j.ejca.2017.07.044
• A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer Cite
  Borges US, Costa-Silva DR, da Silva-Sampaio JP, Escórcio-Dourado CS, Conde AM, Campelo V, et al. A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2017; 34 10.1007/s12032-017-1019-x
• Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study Cite
  Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:613-622 10.1007/s10549-017-4421-3
• Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer Cite
  Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, et al. Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:355-364 10.1007/s10549-017-4329-y
• A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases Cite
  Thangarajah F. A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases. Anticancer Research. Anticancer Research USA Inc.; 2017; 37:1957-1964 10.21873/anticanres.11536
• P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients Cite
  Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0172324 10.1371/journal.pone.0172324
• Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Cite
  Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1061-1069 10.1200/jco.2016.69.4406
• Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers Cite
  Kim HS, Park S, Koo JS, Kim S, Kim JY, Nam S, et al. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0151054 10.1371/journal.pone.0151054
• Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin Cite
  Wang R, Chen S, Jin X, Shao Z. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep30091
• A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients Cite
  Gui Y, Xu S, Yang X, Gu L, Zhang Z, Luo X, et al. A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. Biomarkers in Medicine. Future Medicine Ltd; 2016; 10:771-790 10.2217/bmm-2015-0064
• Prognostic and predictive value of Ki-67 in triple-negative breast cancer Cite
  Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. Impact Journals, LLC; 2016; 7:31079-31087 10.18632/oncotarget.9075
• Prognostic and predictive value of Ki-67 in triple-negative breast cancer Cite
  Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. Impact Journals, LLC; 2016; 7:31079-31087 10.18632/oncotarget.9075
• Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma Cite
  Gonzalez-Sistal A, Baltasar-Sánchez A, Menéndez P, Arias JI, Ruibal Á. Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0151093 10.1371/journal.pone.0151093
• MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer Cite
  Isanejad A, Alizadeh AM, Amani Shalamzari S, Khodayari H, Khodayari S, Khori V, et al. MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer. Life Sciences. Elsevier BV; 2016; 151:30-40 10.1016/j.lfs.2016.02.090
• Fibulin-5 downregulates Ki-67 and inhibits proliferation and invasion of breast cancer cells Cite
  MOHAMEDI Y, FONTANIL T, SOLARES L, GARCIA-SUÁREZ O, GARCÍA-PIQUERAS J, VEGA JA, et al. Fibulin-5 downregulates Ki-67 and inhibits proliferation and invasion of breast cancer cells. International Journal of Oncology. Spandidos Publications; 2016; 48:1447-1456 10.3892/ijo.2016.3394
• Effect of bisphenol A on morphology, apoptosis and proliferation in the resting mammary gland of the adult albino rat Cite
  Ibrahim MAA, Elbakry RH, Bayomy NA. Effect of bisphenol A on morphology, apoptosis and proliferation in the resting mammary gland of the adult albino rat. International Journal of Experimental Pathology. Wiley; 2016; 97:27-36 10.1111/iep.12164
• High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer Cite
  Alba E, Lluch A, Ribelles N, Anton‐Torres A, Sanchez‐Rovira P, Albanell J, et al. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. The Oncologist. Wiley; 2016; 21:150-155 10.1634/theoncologist.2015-0312
• Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast? Cite
  Poulakaki N, Makris G, Battista M, Böhm D, Petraki K, Bafaloukos D, et al. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?. The Breast. Elsevier BV; 2016; 25:57-61 10.1016/j.breast.2015.10.007
• Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies Cite
  Zhang Z, Atwell LL, Farris PE, Ho E, Shannon J. Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies. Public Health Nutrition. Cambridge University Press (CUP); 2015; 19:1288-1295 10.1017/s136898001500244x
• Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ Cite
  Davis JE, Nemesure B, Mehmood S, Nayi V, Burke S, Brzostek SR, et al. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Applied Immunohistochemistry & Molecular Morphology. Ovid Technologies (Wolters Kluwer Health); 2016; 24:20-25 10.1097/pai.0000000000000223
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
  Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
• High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer Cite
  Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2015; 15:204-211 10.1016/j.clbc.2014.12.007
• Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer Cite
  Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. European Journal of Cancer. Elsevier BV; 2015; 51:1874-1881 10.1016/j.ejca.2015.07.003
• Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival Cite
  Lee SK, Bae SY, Lee JH, Lee H, Yi H, Kil WH, et al. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0124658 10.1371/journal.pone.0124658
• Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients Cite
  Ricciardi GRR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, et al. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0128368 10.1371/journal.pone.0128368
• Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer Cite
  Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, et al. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 152:57-65 10.1007/s10549-015-3423-2
• Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma Cite
  Chu Z, Lin H, Liang X, Huang R, Tang J, Bao Y, et al. Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2015; 45:637-641 10.1093/jjco/hyv052
• Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Cite
  Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:16 10.4048/jbc.2015.18.1.16
• Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence Cite
  Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, et al. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2015; 41:548-552 10.1016/j.ejso.2015.01.030
• Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy Cite
  Sheri A, Smith I, Johnston S, A'Hern R, Nerurkar A, Jones R, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Annals of Oncology. Elsevier BV; 2015; 26:75-80 10.1093/annonc/mdu508
• High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer Cite
  Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2015; 15:204-211 10.1016/j.clbc.2014.12.007
• Chemoprevention Activity of 25-Hydroxyvitamin D in the MMTV-PyMT Mouse Model of Breast Cancer Cite
  Rossdeutscher L, Li J, Luco A, Fadhil I, Ochietti B, Camirand A, et al. Chemoprevention Activity of 25-Hydroxyvitamin D in the MMTV-PyMT Mouse Model of Breast Cancer. Cancer Prevention Research. American Association for Cancer Research (AACR); 2014; 8:120-128 10.1158/1940-6207.capr-14-0110
• Impact of sentinel node tumor burden on outcome of invasive breast cancer patients Cite
  Meattini I, Desideri I, Saieva C, Francolini G, Scotti V, Bonomo P, et al. Impact of sentinel node tumor burden on outcome of invasive breast cancer patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:1195-1202 10.1016/j.ejso.2014.08.471
• Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study Cite
  Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, et al. Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e95629 10.1371/journal.pone.0095629
• Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer Cite
  Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2014; 14 10.1186/1471-2407-14-550
• Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2014; 17:40 10.4048/jbc.2014.17.1.40
• Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor Cite
  Narbe U, Bendahl P, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus. Springer Science and Business Media LLC; 2014; 3 10.1186/2193-1801-3-70
• Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer Cite
  Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NRS, Iskander ASM, et al. Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e85311 10.1371/journal.pone.0085311
• Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials Cite
  Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, et al. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Annals of Oncology. Elsevier BV; 2014; 25:618-623 10.1093/annonc/mdt528
• High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer Cite
  Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. The Breast. Elsevier BV; 2014; 23:69-75 10.1016/j.breast.2013.11.007
• Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN Cite
  Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV. Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e78259 10.1371/journal.pone.0078259
• The effect of metformin on apoptosis in a breast cancer presurgical trial Cite
  Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. British Journal of Cancer. Springer Science and Business Media LLC; 2013; 109:2792-2797 10.1038/bjc.2013.657
• Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study Cite
  Petit J, Rietjens M, Botteri E, Rotmensz N, Bertolini F, Curigliano G, et al. Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. Annals of Oncology. Elsevier BV; 2013; 24:1479-1484 10.1093/annonc/mds660
• Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? Cite
  Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, et al. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 87:344-348 10.1016/j.ijrobp.2013.05.052
• Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry Cite
  Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 139:539-552 10.1007/s10549-013-2560-8
• Calcitriol supplementation effects on Ki67 expression and transcriptional profile of breast cancer specimens from post-menopausal patients Cite
  Urata YN, Lyra ECd, Katayama MLH, Basso RA, Assis PEZd, Cardoso APT, et al. Calcitriol supplementation effects on Ki67 expression and transcriptional profile of breast cancer specimens from post-menopausal patients. Clinical Nutrition. Elsevier BV; 2014; 33:136-142 10.1016/j.clnu.2013.04.001
• Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma Cite
  Reyal F, Hajage D, Savignoni A, Feron J, Bollet MA, Kirova Y, et al. Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e55901 10.1371/journal.pone.0055901
• Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Cite
  Kim J, Han W, Moon H, Ahn SK, Shin H, You J, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3221
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Prognostic Value of Molecular Subtypes, Ki67 Expression and Impact of Postmastectomy Radiation Therapy in Breast Cancer Patients With Negative Lymph Nodes After Mastectomy Cite
  Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic Value of Molecular Subtypes, Ki67 Expression and Impact of Postmastectomy Radiation Therapy in Breast Cancer Patients With Negative Lymph Nodes After Mastectomy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 84:1123-1132 10.1016/j.ijrobp.2012.02.047
• Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial Cite
  Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2593-2600 10.1200/jco.2011.39.3769
• High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients Cite
  Vincent-Salomon A, Hajage D, Rouquette A, Cédenot A, Gruel N, Alran S, et al. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. The Breast. Elsevier BV; 2012; 21:380-383 10.1016/j.breast.2012.03.005
• HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ Cite
  Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1160-1165 10.1038/bjc.2012.41
• Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial Cite
  Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, et al. Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial. Cancer Prevention Research. American Association for Cancer Research (AACR); 2012; 5:309-319 10.1158/1940-6207.capr-11-0251
• Prognostic role of CA15.3 in 7942 patients with operable breast cancer Cite
  Sandri MT, Salvatici M, Botteri E, Passerini R, Zorzino L, Rotmensz N, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:317-326 10.1007/s10549-011-1863-x
• Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer Cite
  Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2011; 29:1536-1542 10.1007/s12032-011-0082-y
• Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis Cite
  Manni A. Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. International Journal of Oncology. Spandidos Publications; 2011; 10.3892/ijo.2011.1133
• Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment Cite
  Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-486
• Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Cite
  Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 127:713-720 10.1007/s10549-011-1465-7
• A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression Cite
  Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. The American Journal of Surgery. Elsevier BV; 2011; 201:692-694 10.1016/j.amjsurg.2010.02.015
• Effects of Non-Digestible Carbohydrates on the Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Ovariectomized Athymic Mice Cite
  Kondegowda NG, Meaney MP, Baker C, Ju Y. Effects of Non-Digestible Carbohydrates on the Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Ovariectomized Athymic Mice. Nutrition and Cancer. Informa UK Limited; 2010;:1-1 10.1080/01635581.2010.516871
• Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer Cite
  Winter M, Syddall S, Cross S, Evans A, Ingram C, Jolley I, et al. Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts. American Association for Cancer Research; 2010; 10.1158/0008-5472.sabcs10-p1-11-01
• Reduction in Ki-67 in Benign Breast Tissue of High-Risk Women with the Lignan Secoisolariciresinol Diglycoside Cite
  Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, et al. Reduction in Ki-67 in Benign Breast Tissue of High-Risk Women with the Lignan Secoisolariciresinol Diglycoside. Cancer Prevention Research. American Association for Cancer Research (AACR); 2010; 3:1342-1350 10.1158/1940-6207.capr-10-0022
• Fish oil regulates cell proliferation, protect DNA damages and decrease HER-2/neu and c-Myc protein expression in rat mammary carcinogenesis Cite
  Manna S, Janarthan M, Ghosh B, Rana B, Rana A, Chatterjee M. Fish oil regulates cell proliferation, protect DNA damages and decrease HER-2/neu and c-Myc protein expression in rat mammary carcinogenesis. Clinical Nutrition. Elsevier BV; 2010; 29:531-537 10.1016/j.clnu.2009.12.012
• Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women. Cite
  Fabian CJ, Klemp JR, Kimler BF, Aversman S, Phillips TA, Zalles CM, et al. Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1522-1522 10.1200/jco.2010.28.15_suppl.1522
• Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer Cite
  Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1391-1396 10.1038/sj.bjc.6605655
• Blueberry Phytochemicals Inhibit Growth and Metastatic Potential of MDA-MB-231 Breast Cancer Cells through Modulation of the Phosphatidylinositol 3-Kinase Pathway Cite
  Adams LS, Phung S, Yee N, Seeram NP, Li L, Chen S. Blueberry Phytochemicals Inhibit Growth and Metastatic Potential of MDA-MB-231 Breast Cancer Cells through Modulation of the Phosphatidylinositol 3-Kinase Pathway. Cancer Research. American Association for Cancer Research (AACR); 2010; 70:3594-3605 10.1158/0008-5472.can-09-3565
• Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women Cite
  Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'Hern R, Crowder RJ, et al. Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1161-1167 10.1200/jco.2009.23.9616
• Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis Cite
  Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, et al. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 118:33-43 10.1007/s10549-008-0216-x
• ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies Cite
  Finn RS, Dering J, Ginther C, Press M, Forbes J, Mackey J, et al. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2006; 24:514-514 10.1200/jco.2006.24.18_suppl.514
• Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Cite
  Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. Oxford University Press (OUP); 2008; 29:2162-2168 10.1093/carcin/bgn161
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer Cite
  Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2009; 101:736-750 10.1093/jnci/djp082